Immune modulator drugs improved clinical status, reduced deaths among patients hospitalized with COVID-19

By | June 3, 2022
A large randomized, placebo-controlled clinical trial led by the National Institutes of Health shows that treating adults hospitalized with COVID-19 with infliximab or abatacept – drugs widely used to treat certain autoimmune diseases – did not significantly shorten time to recovery but did substantially improve clinical status and reduce deaths.